A Phase 1, Single-center, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants
Latest Information Update: 04 Oct 2023
At a glance
- Drugs BMS-986419 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 29 Sep 2023 Status changed from recruiting to completed.
- 24 May 2023 Status changed from not yet recruiting to recruiting.
- 12 May 2023 New trial record